Answers are grounded in this paper and cite their sources.
We report the case of a 15-year-old boy diagnosed with congenital nephrotic syndrome (CNS) at one month of age. The genetic testing with exome sequencing identified 2 mutations in the NPHS2 gene. He started treatment with an ACE inhibitor at 9 months. Kidney biopsy conducted at the age of 5 revealed no glomerulosclerosis. He has maintained clinical stability with controlled proteinuria (significant but non-nephrotic range), and no impairment of kidney function. This case shows an atypical evolution of CNS. Considering the identified mutation it would be expected a poor prognosis with early kidney failure and need of kidney replacement therapy. However, this boy, currently 15 years old, has shown a favorable evolution under treatment with an ACE inhibitor.
No takes yet. Share an insight, caveat, or question.
Sousa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: